Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Endo Health Rises On Report It May Put Itself Up for Sale

Don't Miss Out —
Follow us on:

Jan. 30 (Bloomberg) -- Endo Health Solutions Inc., the maker of the painkiller Lidoderm, rose the most in four years after a report said the drugmaker may sell itself.

Endo climbed 11 percent to $31.66 at the close of trading in New York, for the Chadds Ford, Pennsylvania-based company’s largest single-day increase since October 2008. Reuters cited unidentified sources in its article.

“As a matter of company policy, we don’t comment on market rumors,” Blaine Davis, a spokesman for Endo, said in an phone interview.

The drug company said in December it was looking to replace Chief Executive Officer David Holveck, who will retire in May or sooner if a successor is found. Endo also is preparing for generic competition to Lidoderm, its biggest seller, in September. Analysts estimate the medicine generated $922.6 million in 2012, according to data compiled by Bloomberg.

To contact the reporter on this story: Ryan Flinn in San Francisco at rflinn@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.